RCM
LENZ

Radnor Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Radnor Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,200
Closed -$250K – 322
2025
Q3 		$250K Buy
+6,200
New +$228K 0.04% 297

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Radnor Capital Management's LENZ Position: Q4 2025 in Review

Radnor Capital Management sold out of LENZ Therapeutics (LENZ) in Q4 2025, closing a stake of 6,200 shares — an estimated $250K sold.

Radnor Capital Management first reported a position in LENZ in Q3 2025 and held it in 1 quarter. The position peaked at $250K in Q3 2025. 160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

  • Radnor Capital Management reported no remaining LENZ Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Radnor Capital Management sold 6,200 LENZ Therapeutics shares in Q4 2025, an estimated $250K.
  • Radnor Capital Management first reported a position in LENZ Therapeutics in Q3 2025 and held it in 1 quarter.
  • Radnor Capital Management's LENZ Therapeutics position peaked at $250K in Q3 2025.
  • 160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on Radnor Capital Management's 13F filing for Q4 2025, filed 6 Feb 2026.